Scientific Program

Keynote Talks

Abstract

Looking for Precise Markers in Diagnosing Hepatocellular Carcinoma Lecture presented by Nabil Mohie Abdel-Hamid Prof of Cancer Biology, Biochemistry Department, Faculty of Pharmacy, Kafrelsheikh University, Egypt Hepatocellular carcinoma (HCC) is the most common type of 1ry liver cancer, accounting for ~85% of all cases. Overall, it is Sixth most common cancer worldwide, representing about 5.7% of all new human cancer cases ( after Lung, breast, CRC, stomach, prostate).It ranks as 3rd leading cause of cancer-related death in the world, after lung and stomach [WHO]. The number of deaths /year due to HCC is almost identical to its incidence, which highlights the poor prognosis and aggressive nature of the cancer. Each year, more than 600,000 new cases of HCC that occur worldwide. Highest incidence occur in Eastern and Southeast Asia and Central and Western Africa. More than 80% of HCC occur in developing countries, China accounts >50%. AFP level > 20 ng/mL performs poorly as a screening tool, reported sensitivities around 60%. Therefore, AFP used alone may miss up to 40% of HCC. Serum AFP is no longer considered an appropriate surveillance test by American Association for the Study of Liver Diseases due to high rates of false-positive and false-negative results in patients with chronic liver disease. This why, in our laboratories, we spent about 16 years and still looking for new biochemical markers with more precise diagnostic performance. We tried extracellular markers, know to be disturbed during cellular cancer metastasis and progression, some molecular variables, being RNAs of peptidases, proteoglycan lytic enzymes, ployopl profiles, as well as, defective prothrombin form (DCP). We also could expect why and how some cancers are aggressive and highly metastatizing and could guess why AFP is not useful in 2ry HC. Currently, we work on targeting some ECM proteins, using nanosized chemotherapies plus nanosized natural products, carried within specific liposomes and linked to ECM sensitive ligands to minimize chemotherapy side effects, false results and decrease dose duration and frequency.

Biography

Nabil Mohie Abdel-Hamid,currently,he is working as a professor at Biochemistry Department, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in her wide range of publications in various national and international journals. His specialties are in the field of Cancer Biology an pharmcolgy.

Speaker
Nabil Mohie Abdel-Hamid / Dean of Pharmacy College, Kafrelsheikh University, Egypt

Sessions:

Abstract

The utilization of extracorporeal membrane oxygenation (ECMO) and ventricular assist devices (VAD) has increased dramatically as the indications for these treatment modalities continue to expand. In addition, hemocompatibility of the ECMO circuit and VAD has improved significantly in the past decade, allowing for these devices to be used with fewer complications. Management of patients on ECMO and VAD is complex. Unfortunately, even with better hemocompatibility and intense multidisciplinary management, bleeding and thrombotic complications persist. Heparin is usually used in ECMO and acute phase of VAD. Recently bivalirudin, which is a direct thrombin inhibitor, has been increasingly used to anticoagulate patients on VAD and some patients on ECMO. The greatest benefit of bivalirudin is that the bioavailability is much better than heparin since it has a direct thrombin inhibition activity without forming a complex with other proteins. We have used bivalirudin for 8 pediatric patients as an off-label use. The maintenance dose used was 0.33 ± 0.21 mg/kg/hour. Bivalirudin effect was monitored by activated partial thromboplastin time (PTT) with a target range of 1.5-2.5 times normal PTT. We hypothesized that bivalirudin effect could also be monitored by ROTEM. One and a half to 2.5 times normal PTT corresponded to a range of 218 to 368 sec on CT INTEM. CT INTEM correlated well with PTT. Therefore, we concluded that ROTEM can be used to monitor bivalirudin effect. As we continue to further our understanding of anticoagulation for ECMO and VAD, it is likely that bivalirudin will be increasingly used.

Biography

Jun Teruya, MD, DSc, FCAP is a tenured Professor in Department of Pathology and Immunology and Vice Chairman for Education at Baylor College of Medicine, Houston, Texas, USA. He also has secondary appointment of tenured Professor of Pediatrics and tenured Professor of Medicine. He is Chief of Division of Transfusion Medicine and Coagulation, Texas Children's Hospital, Houston, Texas, USA. He has published more than 110 original articles and number of book chapters including in Up to Date. He recently published a textbook of Management of Bleeding Patients, Springer, as a solo editor with more than 50 authors. He became a Chair of Scientific Subcommittee of Plasma Protein Inhibitors of ISTH (International Society of Thrombosis and Haemostasis) in 2017 after its annual meeting in Berlin. He has received a number of teaching awards from medical students, residents, and fellows and has been selected as the Best Doctors in America

Speaker
Jun Teruya / Baylor College of Medicine, USA

Abstract

Aim of this study is to present the latest researches in the field of molecular medicine, in terms of treatments in malignant hemopathies, emerged from the P53 gene deletion in human lymphoma genome. Method: In recent years proved that the best techniques in the investigation of malignant lymphocytes are the Flow Cytometry, Elisa, ICT and Fluorescence in Situ Hybridization (FISH). This method is used as an alternative to chromosomal banding, a conventional application in molecular medicine. Discussion: Recent, endogenous somatic gene therapy research is a basic of trial clinical and therapeutic trial. The DNA is used to treat a disease arising as a result of mutations in chromosomal regions. In the past few years, this method has been included in the treatment of CLL, acute lymphocytic leukemia, [ALL], or multiple myeloma [MM]. Conclusion: The frequencies of P53 gene mutations and deletion in CLL can be categorized as individual biomarkers in proteomic and genomic profile for this type of leukemia that can be implemented in targeted patient treatment of personalized medicine. Keywords: P-53 Gene, Apoptosis, Fluorescence in Situ Hybridization, Phosphatase-Tensin Homolog, Tumor Necrosis Factor Receptor, Antigen Presenting Cells

Biography

Aurelian Udristioiu Complited his Master in Hematology, Laboratory Medicine, University Hospital Careggi, Agienda Carregy, University degli Studi Firenzze, Florence. He is currently working as a Emergency County Hospital Targu Jiu. He had Medical Authority Registrations such as European Specialist In Biochemistry And Laboratory Medicine, License To Practice In: Europen Union-Eu Certificate Of Conformity, Bucharest, Romania. and GMC Reference Number in UK. He has recceived national and international level awards. He has published more than 10 publications. He had done nearly 30 research works

Speaker
Aurelian Udriştoiu / Titu Maiorescu University, Romania

Abstract

JAK2V617F PV is a trilinear myeloproliferative neoplasm preceded by erythromelalgic thrombocythemia, followed by myeloproliferative myeloid metaplasia of spleen and bone marrow and secondary myelofibrosis. With the advent of CALR and MPL mutations of the JAK2 wild type thrombocythemia primary myelofibrosis (PMF) and agnogenic myeloid metaplasia (AMM) without features of polycythemia vera (PV) are not primary or agnogenic anymore and should be relabeled as CALR and MPL thrombocythemia with myeloid metaplasia of the spleen followed by secondary myelofibrosis. The natural history of CALR and MPL thrombocythemia and secondary bone marrow fibrosis clearly differ fromJAK2V617F trilinear essential thrombocythemia (ET), PV, post-ET and post-PV secondary myelofibrosis. Evolution of anemia, splenomegaly and myelofibrosis in MPL, CALR and JAK2V617F trilinear thrombocythemia and PV should be evaluated separately simple because treament options differ.

Biography

Prof. Dr. J. J. Michiels Multidisciplinairy Internist Blood Coagulation and Vascular Medicine Center, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, NL, Professor of Nature Medicine and Health Clinical and Molecular Genetics Blood and Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant Bloodcoagulation and Vascular Medicine Consultant Academic, Pharmaceutical and Industrial Medicine Editor Journal of Hematology and Thromboembolic Diseases, Editor World Journal of Hematology, Editor in Chief World Journal of Clinical Cases

Speaker
Jan Jacques Michiels / University Hospitals Antwerp, Netherlands

Abstract

Honey has been used as the oldest sweeter since ancient times as a nutritive as well as effective remedy, antibacterial; also used topically in treatment of burns and wounds, respiratory diseases, urinary diseases, gastrointestinal diseases, microbial infection, skin ulcers, eczema, psoriasis and dandruff and liver disease. The use of honey is even advocated and embraced by all religious and cultural beliefs. In Christendom, there are references made to the importance of bees and honey in the Bible, and these include the Books of Exodus, Judges, Mathew and Proverbs The religion of Islam recommended the use of honey as food and medicine, and even named an entire chapter in the Holy Qur'an called Surah al-Nahl meaning chapter of the Honey Bee. Honey increases the blood vitamin C level, b-carotene, uric acid, and glutathione reductase, serum iron, copper, zinc, hemoglobin (Hb) and packed cell volume (PCV) in normal subjects. Honey reduces liver enzymes AST and ALT, and fasting blood glucose. Honey lowers the plasma and urinary prostaglandin concentration in normal individuals. It increases the urine volume, free water clearance, filtered sodium and creatinine clearance, and decreases the urea nitrogen and fasting blood glucose. Recently we have found that honey increased nitric oxide (NO) in human saliva. Conclusion: It could be concluded that the honeys modulate hematological parameters. It is recognized as a complementary and alternative treatment in modern medicine. Key words: Potential hematological activity, honey, complementary medicine

Biography

Ahmed Hegazi is currently a Professor of Microbiology and Immunology in the National Research Center, Egypt. Prof. Hegazi received his master’s degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 211 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Dr. Hegazi awards; First Class Decoration of Excellence, Egypt, 1995, The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996, The National Scientific Prize In Biological Sciences, Egypt, 1990, The Scientific Prize of The National Research Center, Cairo, Egypt, 1989, The Second Best Research Paper Award, International Congress of Propolis, Bones Aires, Argentina, 2000, Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006, 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Awarded of Ghazi Wad Allah Salon Prize, 2008, Finally awarded the Merit Ward in Medical Sciences, National Research Centre, Egypt, 2016 and have 4 patents.

Speaker
Ahmed G Hegazi, / Prof.National Research Centre, Egypt

Abstract

Toxoplasma gondii is an important opportunistic infection among human. Toxoplasmosis is one of the most common parasitic and zoonotic worldwide diseases. The present study aimed to investigate the effect of toxoplasma on molecular, physiological and pathological changes in male New Zealand rabbits. Fourteen mature bucks were used and divided into two groups (infected and control). Each animal of infected group (n=9) was inoculated s/c with 150,000 tachyzoites of Toxoplasma gondii of RH strain. The second group was kept as non-infected control. Blood samples were collected pre-inoculation and at weekly post-inoculation (PI) interval for two months and the sera were separated for serological diagnosis and hormonal profile. Tissue specimens were taken for histopathological study. Results indicated that inoculated rabbits showed emaciation and nervous manifestation at the end of experiment. It was shown that testosterone level in the serum of infected rabbits was highly significantly decreased in comparison with that of control group from the first week till the end of experiment. The decrease was gradually during the experimental period. LAT detected anti-toxoplasma antibodies were developed in the sera of all infected animals as well as testosterone level was significantly decreased. Antitoxoplasma antibodies titer was detected markedly in the serum of all T. gondii tachyzoites inoculated rabbits on day 14 post inoculation and the positive titer persisted high for about 2 months. The semen characteristics were affected severely with a parallel significant decrease in the serum testosterone level. Maximum titer (1/1024) was reached the infected animals. The above mentioned toxoplasmic lesions were associated with the presence of tissue cysts of bradyzoites. The most pronounced testicular changes were necrosis and disappearance of epithelial lining of almost all the seminiferous tubules accompanied with intra-tubular multinucleated spermatid giant cells and peritubular C.T. proliferation. It could be concluded that Toxoplasma infection was detected by LAT test and induced testicular dysfunction and had severe adverse effects on the vital organs. Keywords: rabbits, T.gondii, testosterone , latex agglutination test (LAT) histopathology.

Biography

Dr. Ashraf M.A. Barakat Working as Professor of Zoonotic Diseases Department National Research Center, 2010 - up till now, Prof. National Research Center, 2005- Prof. associate National Research Center, 2005, Assoc. Prof. National Research Center, 1995, Researcher National Research Center, 1987, Ass. Lecturer National Research Center, 1983, Ass. Researcher 2. Major research interests include parasite epidemiology, chemo therapeutics, diagnostics, immunomodulatory approaches for the management of parasitic infections. 3. Priority areas include Zoonotic Parasitic infections, cryptosporidiosis, Toxoplasmosis, trypanosomiasis and other tick borne haematozoa, poultry coccidiosis and wild life parasitic infections. He has published more than 55 papers in journals. 4.Besides being on the reviewer of a number of national and international journals,

Speaker
Ashraf Mohamed Abdel khalek Barakat / National Research Centre, Egypt

Abstract

The literature contains little on the prevalence and causes of high predonation haemoglobin levels among blood donors. This study aimed to characterize and develop an algorithm to manage would-be donors with polycythaemia. Materials and Methods In 2008-2009 2 blood donors were diagnosed with polycythaemia vera (PV), which inspired us to initiate the current study. Since the study only one male donor has been found with PV. Between November 2009 and November 2011, we offered haematology consultations to blood donors with repeated haemoglobin concentration (Hb) above the WHO limit for PV (10.2 and 11.5 mM ⁄16.5 and 18.5 g⁄dl for women and men, respectively). Investigation of such donors included Hb, haematocrit, mean cell volume, erythropoietin, ferritin, platelet count and leucocyte count, JAK2 V617 and JAK2 exon12 analysis, as well as other routine measurements. Results Among 46 such donors, 39 had a history of smoking, which contributes to erythrocytosis. Two had PV and of the five with PV including the two before the study and one after 3 were JAK2 V617, 1 JAK2 exon12 and in one we found no known mutation. Five donors had severe hypertension, one of them because of renal artery stenosis, and two had diabetes mellitus. Thus, we found a high morbidity among such donors. Of the 36 others, 30 donated again before May 2012, at which time the Hb was significantly lower. Conclusion We recommend JAK2 V617 and JAK2 exon12 screening and clinical investigation for donors with concurrently high Hb, high haematocrit and relative iron deficiency. We also recommend that they stop or cut down on smoking to reduce the risk of thrombosis in general. We disqualified 10 of the donors.

Biography

Speaker
Karin Magnussen / Inherred Hospital Lillehammer, Norway

Abstract

Hematological and Metabolically Aspects of Laboratory Medicine"continues the analysis of hematologic and metabolic aspects of the 2-nd edition, in the context of international fundamental research. The following chapters convince the readers that this issues is addressed to medical personal for all specialties which can find the ideas on physiology, pathophysiology in the light of current concepts and modern principles. Interests of doctors in all specialties , medical students , staff working in clinical laboratories from 21 countries on five continents where the book is posted on sites, is based on the fact that this paper constitutes a large volume of data, experiences, clinical and laboratory research in a systematic and logical display. The new volume of para-clinical specialty rests on a solid scientific information, rigorously confronted with the author's own experience gained in basic medical education in the country and abroad.

Biography

Aurelian Udristioiu Complited his Master in Hematology, Laboratory Medicine, University Hospital Careggi, Agienda Carregy, University degli Studi Firenzze, Florence. He is currently working as a Emergency County Hospital Targu Jiu. He had Medical Authority Registrations such as European Specialist In Biochemistry And Laboratory Medicine, License To Practice In: Europen Union-Eu Certificate Of Conformity, Bucharest, Romania. and GMC Reference Number in UK. He has recceived national and international level awards. He has published more than 10 publications. He had done nearly 30 research works

Speaker
Aurelian Udristioiu / Titu Maiorescu University, Romania.

Abstract

Background: He1noph ilia is the 1nost frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemoph ilia A) or IX (Hen1ophilia B) in plasma. We ain1ed to identify patients with hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this popu lation and its associated factors. Methods: This study was conducted on patients with hemoph ilia A and B admitted in hospitals of Kermanshah city, referred to coagulation laboratory of Kermanshah blood transfusion organization. Variables including age, sex, family history of the patients in terms of history of he1nophilia and inhibitor formation, development of inhibitor in patients, age at starting the treatment, blood group, severity of hemophilia, average of factors received per month and liver disease •vere assessed in patients. Results: Of 123 patients with hemophilia A, 119 (96.7%) were men. The mea n+SD age of patients with hemophilia A was 25.9+15.74 yea rs. Only five men had developed factor VIII inhibitor. Of 25 patients with hemophilia B, 24 (96%) were 1nen with a mean +SD age of 21.7+15.71 yea rs. Factor IX inhibitor •vas not detected in any patient. There was no association bet ween incidence of inhibitors and age at the onset of the treatn1ent, family history of he1nophilia, blood group, severity of hemophilia, average of received factor per month and liver disease. Ho\-vever, a positive association between incidence of inhibitors and fam ily history of inhibitors was found (P<0.05). Conclusion : Association between family history of inhibitor and incidence of inhibitor formation in hem ophilic patients •vas a new find ing. Therefore thisoutcome and genetic evaluation of these for finding relevant mutat ions should be considered

Biography

Mehrdad Payandeh is a MD from Kermanshah University of medical science (KUMS). He is a Chair of Hemophilia Center of Kermanshah city and Chair ofBone Marrow Transplantation Center of Kermanshah city. He has Eight years of experience in diagnoses and treatment of hematology, oncology, coagulative, BMT patient's disorder in private and university Hospital. He has published more than 70 papers in reputed journals and has been serving as an editorial board member of repute.

Speaker
Mehrdad payandeh / Kermanshah University of Medical Sciences, Iran

Abstract

Busulphan is a myeloablative agent used for conditioning prior to HSCT. Bu is predominantly metabolized through glutathione conjugation, a reaction that highly consumes the hepatic glutathione. N-acetyl-l-cysteine (NAC) is a glutathione precursor used in the treatment of hepatotoxicity caused by acetaminophen and does not interfere with the myeloablative effect of busulphan. We investigated the effect of NAC concomitant treatment during busulphan conditioning on the liver enzymes as well as the clinical outcome of HSCT. Prophylactic NAC treatment upon the start of busulphan conditioning was given to 54 patients. These patients were compared with 54 historical matched controls who did not receive NAC treatment. In patients treated with NAC, AST, ALT and ALP were significantly (P<0.0001, P=0.016 and P=0.0002, respectively) decreased after conditioning compared to their start values. Within the NAC-group, liver enzymes were normalized in those patients (30%) who had significantly high start values. No significant decrease in enzyme levels was observed in the control group. Furthermore, NAC affected neither Bu kinetics nor clinical outcome (i.e. SOS, GVHD and/or graft failure). In conclusion: NAC is a potential prophylactic treatment for hepatotoxicity during busulphan conditioning. NAC therapy is safe and does not alter busulphan kinetics or affect clinical outcome

Biography

Dr. Ibrahim El-Serafi was graduated from the Faculty of Medicine, Suez Canal University, Egypt. After finishing Master degree, he moved to Karolinska Institutet in Sweden for the PhD and defended the thesis in 2014. He has published more than fifteen papers in the field of Molecular Biology and Hematology. His PhD thesis and current postdoc research are about hematological malignancies, solid tumors and personalized treatment prior to stem cell transplantation. He is also leading a study on the biochemical causes of acute kidney injury in burn unit patients. Additionally, he is a reviewer and an editor at several journals.

Speaker
Ibrahim El-Serafi / Karolinska Institutet, Sweden

Abstract

Platelet hyperactivity may be involved in the pathogenesis of both thrombogenesis and hypercholesterolemia. The cholesterol-enriched states may contribute to accelerated development of atherosclerosis. The effect of high cholesterol on platelet activation and on inhibition by coagulation factor Xa, was studied in vitro. Incubation of normal platelets (n=20) with cholesterol-rich dispersion resulted in a small increase of platelet aggregation (PA) and thromboxane A2 (TXA2) synthesis when compared with platelets incubated with cholesterol-normal dispersion. In hypercholesterolemic patients (n=20), ADP-induced PA and TXA2 synthesis showed only small increases over normal controls. Addition of factor Xa (1 unit/ml) prevented the ADP-induced PA and markedly inhibited TXA2 synthesis in normal platelets (1.3±0.2 and 8.7±2.0 pmol TXA2/108 platelets, with and without factor Xa, respectively). However, factor Xa failed to significantly suppress TXA2 synthesis in cholesterol-incubated normal platelets (9.5±1.4 and 11.8±1.3 pmol TXA2/l08 platelets, with and without factor Xa, respectively, p=NS) as well as in platelets from patients with hypercholesterolemia (8.6±4.0 and 10.9±4.9 pmol TXA2/l08 platelets, with and without factor Xa, respectively, p=NS). Exposure of platelets to high cholesterol concentrations, in vitro and in vivo, marginally increased PA and TXA2 synthesis but resulted in loss of responsiveness to factor Xa, which could significantly contribute to platelet activation in hypercholesterolemic states.

Biography

Speaker
Nighat Kahn / Mount Sinai School of Medicine, US

Abstract

The aim of this retrospective study the effect of body mass index on the efficiency of treatment of breast cancer, improve treatment outcomes for breast cancer by individualization of treatment measures taking into account the characteristics of the metabolism of the patient.. Materials and Methods The study included 754 patients with breast cancer between the ages of 30 and 77 (57,6 ± 1) years of age who were treated according to our clinic, department of oncology and medical radiology . Dnipropetrovsk medical academy at Municipal Institution "Dnipropetrovsk City Multi-field Clinical Hospital #4", Dnepropetrovsk state medical academy from 2005-2016. All patients were evaluated according to the following data: stage of the disease, age and BMI at the time of diagnosis, the size, histological type and metastases. IHC type ,MRI methods, Bioelectrical impedance analysis, Ultrasounds analysis. Tumor size was evaluated after measuring its maximal diameter and distributed in accordance with the International TNM-classification (7th edition, 2009). The histological type and degree of differentiation of the tumor was evaluated respectively by the National Standards of diagnostics and treatment of malignant neoplasms, reflecting the recommendations of leading international organizations. BMI is calculated by the formula: I = m×h2, where m - body weight (kg); h - height (m). According to these calculations the patients were divided in accordance with the WHO criteria into the following groups: those with a BMI <25 kg/m2 - normal or underweight; from 25 to 29.9 kg/m2 - overweight; > 30 kg/m2 - obese. The material for the histopathological study was obtained during surgery. We examined the relative risk of relapse and death with regard to the BMI categories adjusting for eight factors known to be predictors of disease-free survival (DFS) and overall survival (OS): menopausal status, nodal status tumor size, vessel invasion, estrogen receptor (ER) status, progesterone receptor status, tumor grade and treatment regimens.ECOG. By analyzing archival material to consider the particular response to systemic treatment of breast cancer women with deficiency of body weight, normal, high and overweight. Explore options for determining the individual characteristics of lipid metabolism of patients with breast cancer and their possible use for predicting the effectiveness of treatment. To determine the lipid metabolism will be applied anthropological research methods, bioimpedansnoho measurement, CT. Results. In this retrospective study, among 754 patients with breast cancer, 45% were identified with excess body weight, and 31% - of various obesity degree. Patients with a BMI <25 kg/m2 were significantly more diagnosed with stage 2 breast cancer triple negative. BMI> 30 kg/m2, 10 % more often associated with metastatic RLN, which is an indirect sign of higher metastatic potentials. Patients with normal BMI had significantly longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate or obese BMI in pairwise comparisons adjusted for other factors. We found a strong correlation between obesity and lymph node involvement These observations suggest that obesity may potentiate the metastatic spread of breast tumors. Distant metastases were also found more often in obese patients in bone or visceral sites in patients <45 years of age at diagnosis. Patients with normal mass by IHC with triple negative cancer 45% and 20% with BRCA + and patients with obesity 55% that’s with IHC luminal A.B but 2 group receive L carnitine in group with L carnitine by ECOG better and calendar Chemotherapy was as planed and less Adverse Advents than group Patients without support L Carnitine And less hematological complication . Conclusions. In conclusion, this retrospective investigation of our patient demonstrates that BMI is an independent prognostic factor for OS in patients with breast cancer. We have supporting evidence that obese BMI represents a poor risk feature for outcome, especially in pre-/premenopausal patients, most of whom received chemotherapy without hormonal therapy. A lifestyle intervention reducing dietary fat intake, with modest influence on body weight, may improve relapse-free survival of breast cancer patients receiving conventional cancer management. Longer, ongoing nonintervention follow-up will address original protocol design plans, which requires 3 years of follow-ups after completion of recruitment. The prominent role of L–carnitine in the present study belongs to the level of Her-2/neu,Ki67, which weresignificantly reduced after L-carnitine supplementation. Thus, L-CAR as add on therapy to TAM, in addition to its ability to foster the immune system and improve the patients` fatigue and quality of life, may offer better cancer prognosis, which may be, in part, a prospective trial to overcome Chemotherapy and letrazol resistance. Key words: body mass index, breast cancer, obesity, overall survival

Biography

Mohammed Hojouj is Master of medicine. Mohammad I.M.Hojouj had been studied for Masters Degree and performed thesis Effect of hematologic complications effectiveness of chemotherapy for metastatic breast cancer from 01.09.2012 to 31.08.2014. A member of The National Comprehensive Cancer Network NCCN, a member of the European Association of Physicians in Germany( NGO), member of the international conference, Speaker of the international conference in the United Arab Emirates 2015, a member of the Association of Arab doctors in Ukraine. Actual Member of the American Association of Clinical Oncology (ASCO). Has experience of more than 9 international clinical researches as Sub investigator. He gives great attention to the educational process, organization and conduction of clinical trials in oncology practice. Responsible for the educational process at the department (Foreign students).

Speaker
Mohammed Hojouj / Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Ukraine

Abstract

Rituximab is a well-known anti CD20 that has made a breakthrough in the management of B-cell neoplasms, and has shown various activities in autoimmune diseases at a much lower dose (100 mg in total). Several studies have confirmed the efficacy of low dose Rituximab in the treatment of ITP, yet, many physicians still use the standard dose (375 mg/m2). Aim: The aim of this presentation is to draw physician’s attention to the fact that: Low dose Rituximab is effective in patients with ITP, with significant cost savings. Methods: We used low dose Rituximab, a total of 100 mg intravenously weekly for 4 weeks in 2 males, adult patients with severe ITP, who failed to respond to corticosteroids and immunoglobulin therapy. Both patients responded very well to low dose Rituximab with sustained normal platelet count (table 1). Table 1; cases, Case Age (years) Gender Platelets Pre-Rituximab Platelets Post Rituximab. Follow up after Rituximab (Months) 1st 30 Male 3x109/l 313x109/l 6 2nd 40 Male 1x109/l 197x109/l 15 Table 2; Cost analysis: Rituximab dose Cost/dose (€) Cost/ course = 4 doses (€) Infusion time (hours) Low dose = 100 mg 326.44 1,306 1 Standard dose 375 mg/m2 (average 700mg) x 4 2232.22 8,929 4 Several studies and case reports have shown that low dose rituximab is effective in the treatment of severe, refractory ITP. Conclusion: Low Dose Rituximab is effective in the treatment of ITP, Implementation of low dose Rituximab will lead to huge cost saving, with possible reduction in adverse effects. Literature references that support this conclusion will be presented

Biography

Dr. Abdulkareem Mohammed Al Momen Obtained his MB, BS,in 1976 from King Saud University, Riyadh.He got his Fellowship in 1986 from the Royal College of Physicians

Speaker
Abdulkareem Almomen / Professor of Medicine and Hematology National Blood and Cancer Center, Saudi Arabia

Abstract

The tumour suppressor gene p73 is a structural and functional homologue of p53 gene, which plays a key role in the regulation of cell cycle control, apoptosis and cell growth. The p63 and p73 negatively-deregulated isoforms are known to play an important oncogenic role in cancers and contribute to chemoresistance. There are two linked polymorphisms in the non-coding region of exon 2 of p73 gene leading to the formation of a stem-loop structure which influences’ p73 expression and cancer development. The aim of the present study was to investigate the association of p73 G4C14-A4T14 dipolymorphism with CML susceptibility, and its association with clinico-pathological characteristics of CML. Methods: A case-control study was conducted in 212 CML patients and 212 healthy volunteers. 2ml blood samples were collected from all the individuals (414) for DNA extraction and genotyping after obtaining IEC approval. PCR-CTPP was used to determine the genotypes of p73 and the results correlated with clinical features and chemotherapy refimens. Results: We found that GC/AT and AT/AT genotypes were independently associated with CML development (OR= 1.78, 95% CI= 1.06-2.98, p= 0.02 and OR= 5.32, 95% CI= 0.63-44.76, p= 0.02). The GC/AT, AT/AT genotypes were associated with advanced CML stages (p<0.0001), high blast percentage (p=0.023). GC/GC was found to be associated with leukopenia (p= 0.047) and moderate leukocytosis (p= 0.022). Patients with GC/AT showed good response to imatinib therapy (p= 0.042). Correlation of p73 genotypes with prognostic risk scores revealed that GC/AT and AT/AT showed risk for high Sokal score (p= 0.024); GC/AT exhibited risk for intermediate Hasford risk (p= 0.031), high Hasford score (p= 0.014). Conclusion: This is the first report showing p73 dipolymorphism associated with an increased risk of CML, and the genotypes serve as the useful biomarkers in predicting the disease progression and disease prognosis. Key words: p73 gene; G4C14-A4T14 Dipolymorphism; Chronic Myeloid Leukemia risk; CML progression; Imatinib therapy; Prognostic risk scores.

Biography

Kaiser Jamil is the Principle Investigator and the Head of Genetics Department, having published more than 250 papers in journals of repute and guided 34 scholars for PhD degree. During the last decade following her instincts, she has taken up several projects related to human health, for ‘War against Cancer’ she has contributed in the field of biomarkers in breast cancer, leukemia, and head and neck cancer. Her work is on SNPs of drug metabolizing genes in cancers and it has been published in peer reviewed journals, unfolding the mechanisms of several genes and other genes which network with these genes, elucidating drug-gene interactions. She has also contributed on the role of some signaling pathways such as tyrosine kinase inhibitors (TKI) and MAPK in haematological malignancies and HNC. Her research continues to unravel genotypes leading towards personalized medicine

Speaker
Kaiser Jamil / Bhagwan Mahavir Medical Research Centre, India

Sessions:

Abstract

Improved Clinical, Laboratory, Molecular, and Pathological (CLMP) 2017 criteria for myeloproliferative neoplasms (MPN) defne the JAK2V617F trilinear MPNs as a broad continuum of essential thrombocythaemia (ET), polycythaemia vera (PV), masked PV, and post-ET or post-PV myelofbrosis (MF). Normal versus increased erythrocyte counts (5.8x1012/L) on top of bone marrow histology separate JAK2V617F ET and prodromal PV from early and classical PV. Bone marrow histology of the JAK2V617F trilinear MPNs show variable degrees of normocellular megakaryocytic, erythrocytic megakaryocytic and erythrocytic megakaryocytic granulocytic (EMG) myeloproliferation, peripheral cytoses, and splenomegaly related to JAK2V617F allele burden. MPL515 thrombocythaemia displays predominantly normocellular megakaryocytic proliferation. CALR thrombocythaemia intially presents with megakaryocytic followed by dual granulocytic and megakaryocytic myeloproliferation without features of PV. The megakaryocytes are large, mature, and pleomorphic with hyperlobulated nuclei in JAK2V617F ET and prodromal, classical, and masked PV. The megakaryocytes are large to giant with hyperlobulated staghorn-like nuclei in MPL515 thrombocythaemia. The megakaryocytes are densely clustered, large, and immature dysmorphic with bulky (bulbous) hyperchromatic nuclei in CALR thrombocythaemia and MF. Keywords: Myeloproliferative neoplasms (MPN), essential thrombocythaemia (ET), polycythaemia vera (PV), primary megakaryocytic granulocytic myeloproliferation (PMGM), thrombocythaemia, myelofbrosis (MF), JAK2V617F, JAK2 exon 12; MPL515, calreticulin, triple negative.

Biography

Prof. Dr. J. J. Michiels Multidisciplinairy Internist Blood Coagulation and Vascular Medicine Center, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, NL, Professor of Nature Medicine and Health Clinical and Molecular Genetics Blood and Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant Bloodcoagulation and Vascular Medicine Consultant Academic, Pharmaceutical and Industrial Medicine Editor Journal of Hematology and Thromboembolic Diseases, Editor World Journal of Hematology, Editor in Chief World Journal of Clinical Cases

Speaker
Jan Jacques Michiels / University Hospitals Antwerp, Netherlands

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common hematologic malignant diseases which had especially to the elderly. It is particularly interesting that, although known as a pathological entity and studied for decades, CLL remains an incurable disease in patients who require therapeutic intervention. While some patients had quickly disease evolution and with a final immediately, other patients can survive for years without even require treatment. In the normal cells, the flux of glucose is directed in a path lipogenic de novo, which is regulated in part by the enzyme phosphoinositol-3 kinase (PI-3K) activation dependent on the ATP-citrate lyase (ACL), which is a cytosolic enzyme which catalyzes the production of acetyl CoA citrate. Inhibition of ACL leads to a loss of B cell growth and viability of the cell [1]. Phosphatase-tensin homolog (PTEN) is a tumor suppressor protein that regulates enzyme phosphoinositol-3 kinase (PI-3K). Several mutations or loss of function of PTEN affects lipid phosphatase activity which leads to development of a variety of cancers. Of the three residues of component PTEN, residue R-335 was observed as important to interact with the membrane cellular, in common with several other mutations in the germ line and was associated with cancers inherited [2]. Also, the cytosolic NADPH may be limited to cell proliferation, since its level is essential to reduce the equivalents of fatty acid and cholesterol biosynthesis, and for the modulation of the oxidative stress. It is know from experimental studies that metformin, an anti-hyperglycemic agent induces apoptosis in CLL cells. The main effect of this drug in the biguanide family, is to reduce acute hepatic glucose production, particularly by a transient inhibition of mitochondrial respiratory chain. It has been suggested that metformin may inhibit the growth of cancer cells by reducing cellular energy state [3]. In cancer metabolism research in the past decade, increased understanding of the importance of glycolysis associated with cell growth and proliferation. Development of hypoxia in tumors is accompanied by a significant accumulation of nucleoside adenosine (ADO) in the range of 50-100 μM. By contrast, ADO levels in normal tissues have been found to be 10-50 μM. It has been proven that ADO can directly boost tumor cell proliferation and angiogenesis [4]. Latest studies have shown that signaling lymphocyte B cell receptor (BCR) is regulated in part by the amount of cholesterol in the cell membrane. It has been found that statins (Lovostatin), pharmacological inhibitors of cholesterol synthesis, induce apoptosis of CLL cells in vitro and in vivo. In addition, ectopic expression of CD5 in B-cell line stimulates the transcription of genes involved in cholesterol synthesis [5]. B lymphocytes express a variety of specific surface antigens which can be targets for the chimeric antigen receptor (CAR) that destroy leukemia cells.

Biography

Aurelian Udristioiu Complited his Master in Hematology, Laboratory Medicine, University Hospital Careggi, Agienda Carregy, University degli Studi Firenzze, Florence. He is currently working as a Emergency County Hospital Targu Jiu. He had Medical Authority Registrations such as European Specialist In Biochemistry And Laboratory Medicine, License To Practice In: Europen Union-Eu Certificate Of Conformity, Bucharest, Romania. and GMC Reference Number in UK. He has recceived national and international level awards. He has published more than 10 publications. He had done nearly 30 research works

Speaker
Aurelian Udristioiu / Titu Maiorescu University, Romania

Abstract

Hematopoietic stem cell transplantation (HSCT) is a curative treatment for malignant and non-malignant diseases; however, regimen-related toxicity (RRT) is a major drawback. The present study includes 437 allogeneic or autologous transplanted patients from five centers in Sweden between 1987 and 2002. All patients were conditioned using busulphan (Bu)-cyclophosphamide. We investigated the effect of therapeutic drug monitoring and dose adjustment of Bu on the occurrence of RRT. Busulphan pharmacokinetics were followed by measuring the area under the concentration-time curve (AUC) after the first dose and the mean Bu plasma trough levels from dose 3 through dose 16 in all patients. Busulphan doses were adjusted in 247 patients whenever appropriate. Dose adjustments decreased the variation in exposure to Bu among and within the different age groups. Sinusoidal obstruction syndrome (SOS) was diagnosed in 4.8% of patients in the dose-adjusted group compared to 16.3% of patients without dose-adjustment (P<0.001). Busulphan plasma concentrations above 600 ng/ml predisposed to SOS. Hemorrhagic cystitis (3.2% vs. 15%, P<0.001) and interstitial pneumonitis (4.8% vs 16%, P<0.001) was decreased in the dose-adjusted group. The 5-years overall survival was significantly (P<0.01) higher among the Bu-dose adjusted patients, 63%, compared to 49% in non-dose adjusted patients. Moreover, relapse incidence was significantly (P<0.01) lower (28%) among dose-adjusted compared to 39% observed in non-dose adjusted patients. These results show, that therapeutic drug monitoring and dose adjustment of Bu during myeloablative conditioning regimen decrease the occurrence of RRT.

Biography

Moustapha Hassan is professor of Transplantation Research at Karolinska Institutet, Sweden as well as the director of Preclinical Laboratory at Karolinska University Hospital, Huddinge, Sweden. He is a consultant to several hospitals for personalized treatment prior to stem cell transplantation and treatment for hematological malignancies treatment efficacy and reducing side effects for transplanted children, and on optimizing treatment with stem cell transplantation. Professor Hassan developed a liposomal formulation intravenous administration. Professor Hassan’s current research projects focus on personalizing treatment through genome analysis, nanomedicine and improvement in pre-transplant medicine

Speaker
Moustapha Hassan / Karolinska Institutet, Sweden

Abstract

Background: Triple negative breast cancer (TNBC), characterized as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 Her2 negative and accounting for 10-l7& of alI hreast carcinomas, is only partially responsive to chemotherapy and suffers from a lack of clinically established targeted therapies. The aim of the current study was to evaluate the patterns of treatment and clinicopathology figures in Kurdish patients with triple-negative breast cancer, and to compare these to other reports. Materials arid Method.s: Between 20111 and 2014, 950 breast cancer patients were referred to our clinic. There were 74 female patients with TNBC, including 70 patients was invasive ductal carcinoma entered into our study. ER and PR positivity was defined as positive immunohistochemical staining in more than l0'7c of tumor cells. Immunohistochemistry assay with anti-HER2 antibodies was used to identify HER negative (0 and 1+) or positive (2+ and 3+). HER2 gene amplification was determined by fluorescent in situ hybridization (FISH). Overall survival (OS) was plotted with GraphPad Prism S Software using Kaplan-Meier and log-rank tests for comparison of results. Results: The mean age in the first diagnosis for 70 patients with triple TNBC and invasive ductal carcinoma was 49.6 years that range of age was 27-82 years. All of the patients were female. Of 70 patients, 23 patients had metastasis. Thirty-two patients (45.7&) were treated with tamoxifen and 39 (55.7&) with radiotherapy. Three-year, 5-year and 10-year OS rates for all patients were 829a, 72'7o and 64a , respectively. Conclusions: The OS in our West Iran TNBC patients is less than reported elsewhere. However, treatment with combination of tamoxifen plus mdiation increases the OS and reduces the mortality rate. Keywords: Overall survival - radiation — tamoxifen —TNBC - Kurdish Iran

Biography

Mehrdad Payandeh is a MD from Kermanshah University of medical science (KUMS). He is a Chair of Hemophilia Center of Kermanshah city and Chair ofBone Marrow Transplantation Center of Kermanshah city. He has Eight years of experience in diagnoses and treatment of hematology, oncology, coagulative, BMT patient's disorder in private and university Hospital. He has published more than 70 papers in reputed journals and has been serving as an editorial board member of repute.

Speaker
Mehrdad payandeh / Kermanshah University of Medical Sciences, Iran

Abstract

Background: Daratumumab, a human CD38-specific IgG1 monoclonal antibody has been successfully used in clinical practice for relapsed /refractory multiple myeloma (RR MM) since 2015. Based on published landmark studies, various daratumumab-based combinations have become some of the essential treatment regimens in RR MM for second-line setting and beyond.1.2,3 Daratumumab is generally well tolerated. Infusion-related reactions were reported in 47-71% of the patients treated with daratumumab in the landmark trials.4,5 Here we report our experience on daratumumab premedication protocol that is associated with significantly reduced incidence of infusion-related reactions. Methods: Patients received daratumumab at 16 mg per kilogram once weekly (8 doses), twice monthly (8 doses), and monthly thereafter, until progression of disease. The premedication regimen consisted of acetaminophen 650mg po once, diphenhydramine 50mg po once, dexamethasone 20mg IV once, montelukast 10mg po once, administered 30 minutes prior to daratumumab infusion. Patients with history of COPD or asthma received albuterol inhalation at the completion of infusion. Vitals signs were monitored prior to, every 15 minutes during the first hour, then hourly during the infusion, and at 30-60 minutes after completion of infusion. The frequency and severity of the observed infusion-related reactions were assessed and graded. Results: Data from 25 patients treated with daratumumab at our institution were examined. The average number of cycles of daratumumab treatment were 6.35 (range 1-18). Infusionrelated reactions during daratumumab infusion were very infrequent and mild. The overall incidence of infusion-related reaction was 8% (2/25) and all were grade1. None of the patients developed any infusion reactions graded 2 or above. Only two patients experienced rigors. On both occasions the reactions occurred during the first dose of daratumumab administration, and were relieved with the administration of H1, H2 blockers and Demerol. Conclusion: Our protocol of daratumumab premedication with acetaminophen, diphenhydramine, dexamethasone, montelukast, and albuterol is very effective, prevents the majority of reactions, and leads to significantly less frequent infusion-related reactions as compared with the reported experience in published studies with daratumumab.

Biography

Dr. Neparidze obtained medical degree from Aieti Medical School in Tbilisi, Georgia in 2000. She subsequently completed Postdoctoral Research Fellowships at Emory, Northwestern and Yale Universities, followed by Internal Medicine Residency and Hematology/Medical Oncology Fellowship at Yale University. She is an assistant professor at Yale University School of Medicine, Section of Hematology, with clinical interests in multiple myeloma and benign classical hematology. Her research focus is on multiple myeloma, with specific interests in advanced imaging and tumor heterogeneity in myeloma, as well as strategies for intensification of maintenance therapy in multiple myeloma.

Speaker
Natalia Neparidze / Yale University School of Medicine, USA

Abstract

Introduction: The hypomethylating agents (HMAs) azacitidine and decitabine are DNA methyl-transferase enzyme inhibitors and are approved for treatment of all subtypes of MDS (Myelodysplastic syndrome) and low blast count AML (Acute Myeloid Leukaemia) for more than a decade. They have changed the outlook of patients with AML and MDS not fit for intensive therapy and stem cell transplant. Present situation: They have shown promising results in terms of better overall response rates and overall survival. In spite of this, they are limited by response seen in around only one third of the patients and lack long term responses. Studies have evaluated factors predicting response to Hypomethylating agents and have revealed variable results with respect to cytogenetics, molecular mutational status and patient and disease related factors. The combination of hypomethylating agents with Histone Deaceytlase inhibitors, lenalidomide, erythropoietin and thrombopoietin stimulating agents have not shown superiority over HMA’s alone. In patients with failure to response to one hypomethylating agent, there is some data about sequential use of another. In addition to the approved indications, use of HMA’s has been explored as immunomodulators in stem cell transplant settings. HMA’s are also used in refractory or relapsed AML with a complete response (CR)/CR with incomplete count recovery (CRi) rate of approximately 16%. Mechanism of resistance and therapeutic implications: One important reason for suboptimal responses is that the underlying mechanism of action and resistance to HMA’s are poorly understood. HMA’s do not only lead to promoter hypomethylation of silenced tumor suppressor genes but were also found to have pleiotropic effects on cell differentiation, senescence, apoptosis, angiogenesis and the immune system. Programmed cell death protein 1 (PD-1) signalling may be involved in MDS pathogenesis and resistance to HMA’s. In MDS patients resistant to HMA’s up regulation of programmed death ligands 1 and 2 (PD-L1 and PD-L2) and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) was observed. Another proposed mechanism of resistance is increased expression of BCL2L10 (an antiapoptotic Bcl-2 member). Recently combination of HMA’s with PD 1 inhibitors, anti CTLA-4, mutikinase inhibitor Rigosertib and Bcl-2 inhibitor Venetoclax has shown some modest results. This needs further evaluation in large scale phase 3 studies. Future directions: The oral formulation of azacitidine CC-486 and novel hypomethylating agent guadecitabine (SGI-110, GDAC) have been tried in early phase trials in frontline as well as HMA failure situations and needs further exploration. A newer generation of HMA’s is being developed, such as ASTX727, a combination pill of decitabine and a cytidine deaminase inhibitor, E727. To optimize therapeutic selection, combination with targeted therapy as per mutational status (IDH, TET2 AND SF3B1) may also herald a new beginning in future. The real world data about the impact of HMA’s in treatment of unfit AML and MDS patients in terms of survival and quality of life needs to be explored across the globe

Biography

Sonali Sadawarte is fully trained and qualified haemato-oncologist and bone marrow transplant physician and have 10 years of experience in treating haemato-oncology and general haematology patients. I hold qualifications to practice in India as well as in Australia.I am a member of many international societies and have international publications to my credit. My special interest is in providing Haemato-oncology services and active participation in clinical research.

Speaker
Sonali Sadawarte / KIMS Hospital, India

Abstract

Acute promyelocytic leukemia (APL), was first described as an entity in1957 in Norway and is characterized by a translocation between the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17, has become a model for targeted treatment of cancer. Advances in our understanding of the fundamental biology of this disease have led to the development of tools for diagnosis, monitoring of minimal residual disease, and detection of early relapse. Differentiation therapy with all-trans retinoic acid in combination with chemotherapy has significantly improved survival in patients with APL. Moreover, arsenic trioxide, which induces differentiation and apoptosis of APL cells, has become standard treatment for relapsed disease, and its role in the treatment of newly diagnosed APL is under active investigation.

Biography

Speaker
Saeed Nasouhi Pur / Tabriz university of medical sciences, Iran 

Abstract

Recent advances in decentralized modalities and lossless archetypes are based entirely on the assumption that Markov models [4] and Internet QoS are not in conflict with extreme programming. It might seem counterintuitive but fell in line with our expectations. This is a direct result of the investigation of gigabit switches. Therefore, Scheme and the understanding of checksums have paved the way for the exploration of the UNIVAC computer. An unfortunate method to fix this obstacle is the analysis of B-trees. For example, many methodologies allow the development of superpages. The disadvantage of this type of approach, however, is that write-ahead logging can be made compact, multimodal, and cooperative [4]. The drawback of this type of solution, however, is that the well-known extensible algorithm for the refinement of gigabit switches by Zhou et al. [4] runs in Θ( n ) time. Indeed, DHTs and the Turing machine have a long history of collaborating in this manner. Our system is impossible. We propose an analysis of e-commerce (StocahGrinder), which we use to argue that the memory bus and XML are often incompatible. We view "fuzzy" networking as following a cycle of four phases: study, study, prevention, and investigation. In the opinions of many, StocahGrinder learns embedded archetypes, without synthesizing 802.11b. even though conventional wisdom states that this challenge is never fixed by the synthesis of Web services, we believe that a different solution is necessary. Even though conventional wisdom states that this question is rarely answered by the refinement of the partition table, we believe that a different method is necessary. Therefore, StocahGrinder is based on the simulation of thin clients. Many scholars would agree that, had it not been for superblocks, the construction of telephony might never have occurred. Given the current status of metamorphic models, security experts obviously desire the emulation of the Internet. We construct new semantic symmetries, which we call StocahGrinder.

Biography

Speaker
Conferma Novembre / national university of applied medicine, Botswana

Abstract

Gliomas are the most frequent brain tumors worldwide. Gliomas make up about 30% of all brain and central nervous system tumors, and 80% of all malignant brain tumors. Diagnosis of the glioma tumor type and its grade is a most essential step in order to suggest a right treatment for the glioma patients. We present a comprehensive study of the different types of the tumors with a low burden in plasma matched with the cfDNA extracted from a clinical cohort of patients' plasma in order to find unique tumor mutations as biomarkers. We successfully detected the glioma specific mutations for the highly frequently mutated genes such as IDH2, PDGFRA, NOTCH1, PIK3R1 and 30 other genes. We identified the particular mutations of the cfDNA isolated from the plasma of the glioma patients, followed by the DNA-sequencing and our predictive bioinformatics analysis. We have collected the matched tumor and cfDNA mutations to uncover the tumor grade as well as its heterogeneity using our unique measurement of the mutations coverage by the DNA-seq reads. Moreover, we used our previously published methods to uncover unique fusions in the glioma patients and its alterations in the protein-protein interactions networks to understand the tumor prognosis. For the best of our knowledge, our study is the most advanced study in the field of the liquid biopsy for the brain cancer tumors, and it will provide a quick and safe non-invasive diagnostic method for the glioma patients, as it uncovers the tumour sub-types using unique biomarkers. This will provide the best personalized treatment for the highly complicate disease and will eventually bypass the existing "wait-and- see" method for prognosis.

Biography

Milana Frenkel-Morgenstern has completed her Ph.D at the age of 32 years from Weizmann Institute of Science and postdoctoral studies from Spanish National Cancer Research Centre (CNIO). She has published more than 20 papers in reputed journals and serving as an editorial board member of repute. She is a founder of the Art in Science competition at the ISMB conference since 2008, a chair of the ISCB affiliated Israeli Bioinformatics group, and a head of the Cancer Genomics and BioComputing group in the Azrieli faculty of Medicine, Bar-Ilan University.

Speaker
Milana Frenkel-Morgenstern / Bar-Ilan University, Israel

Abstract

To date, blood transfusion and disorders (BTDs) govern and dominate health system in the clinical applications. Although the aim is to bridge the basic science to the clinic, there is still little known about standard blood transfusion and related disorders and remained to be elucidated. In the last decades, the most groups gather together and make appointments and agreements for the next year’s standard despite of all side effects and errors that recently occurred after the blood transfusion. It is logic to be assumed that potential future patients expect a reliable standard blood transfusion without any side effects. Different publications showed that higher mortality and morbidity caused by such side effects after blood transfusion specially platelets. To shed more light on the ABC of the storage activities Sciences (SASs) and the BTDs, it is possible to divide the situation into three categories, which can refer to the aim of this paper as well namely A) the SASs B) the BTDs and C) effects of SASs on the BTDs.

Biography

Speaker
Bahram A. Badlou / BBAdvies and Research, Netherlands

Abstract

Background: The normal lifetime of a red blood cell is usually about 120 days. Any process that can disrupt this normal life of a red blood cell can cause anemia. Anemia is worldwide problem that affects 24.8% of the population (95% CI: 22.9- 26.7%) which corresponds to 1.62 billion people (95% CI: 1.50-1.74 billion). Preschool children are the most affected, that is why the highest prevalence was observed among children (47.4%, 95% CI: 45.7-49.1) and the lowest among men (12.7%, 95% CI, 6-16.9%). However, non-pregnant women constitute the population group with the highest number of people affected (468.4 million, 95% CI 446.2-490.6). In Cameroon, the prevalence of anemia among children under 5 years of age was 63.30 in 2011. Over the past 21 years, its highest value was 77.40 in 1990, while its lowest value was obtained in 2011. Anemia is considerate as a proxy biomarker to monitor changes in malaria epidemiology. Very often, malaria patients always developed anemia due to the destruction of red blood cells by Plasmodium. Meanwhile the socio-cultural medicine specifically in Cameroon and generally in Africa has many medicinal plants used for the management of post malaria anemia. Therefore the present study was designed to identify and document plants used in treatment of anemia. Methods: To achieve this goal, 100 people, including 41 specialized traditional healers, 23 anemic patients identified by a doctor and 38 healers who have no medical experience but who use plants to treat visible signs, symptoms and diseases complications including anemia. Results and discussion: Six plants have revealed very effective in the management of post malaria anemia particularly in children. There is a good concentration of iron or magnesium in these plants. Conclusions: This work is important for tropical countries with the strong prevalence of anemia due to the epidemical statute of malaria. It would help to produce anti-anemic phytodrugs worldwide. Key words: Indigenous knowledge, post malaria anemia, anti-anemic plants, Cameroon

Biography

Dr. Nole Tsabang is a previous researcher of the Institute of Medical Research and Medicinal Plant Studies (IMPM) and part time lecturer at the Faculty of Medicine and Biomedical Sciences since 6 years and at the Higher Institute of Environmental Science. He also work as an Independent Consultant with NGOs including Heifer International Cameroon, Alpha Technology, Poëry Environmental Sa-Rio Tinton Alcan, Rainbow Environmental Consult-Caminex and Global Water Partnership Central Africa and has been associated with Pr. Paul Bernard Tchounwou and Dr. Clement Yedjou, lecturers of Jackson State University for three years. Dr. Nole Tsabang is involved in the publication of five books, four of which are on the ethno veterinary practices and the last on medicinal plants used to treat diabetes. He serves as reviewer for two International journals and for IFS. In addition, he has published articles, submitted manuscripts and have books in writing.

Speaker
Nole Tsabang / University of Yaounde, Cameroon

Abstract

A number of genetic polymorphisms associated with thrombosis were implicated as genetic modifiers of Sickle cell disease (SCD). In the present study, we investigated the association between genetic polymorphisms in SERPINC1 (rs2227589 G/A and rs3138521, DNA length polymorphism) and GP6 (rs1613662) A/G and SCD. The study included 50 Egyptian children with SCD and 41 age- and sex-matched controls. Thrombin-antithrombin plasma levels were estimated by enzyme-linked immunosorbent assay (ELISA). GP6 (rs1613662) A/G and SERPINC1 (rs2227589) G/A were performed by restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR). SERPINC1 (rs3138521) was detected by PCR. Insignificant increase in AA genotype and A allele frequency in GP6 (rs1613662) A/G gene was observed in both study groups. In SERPINC1 (rs2227589) G/A gene, GG genotype and G allele were increased in both groups compared with other genotypes/alleles, however, no significant difference was detected. Significant increase in international normalization ratio (INR) was detected in SCD patients with GA polymorphism (p<0.05) with positive correlation (r= 0.376, p<0.01). A significant elevation in PTT was reported in SCD patients with SS polymorphism (p<0.01) with positive correlation (r=0.319, p<0.05). In conclusion, our preliminary results showed no significant association between SERPINC1 gene and GP6 gene polymorphisms and SCD in Egyptian patients. Key words: SERPINC1 - GP6 – Sickle cell disease – Venous thrombosis – gene Polymorphism.

Biography

Speaker
Hisham A. Ismail / Sadat university, Egypt

Will be updated soon...


Change Color